About PER - Advisory Boards

JCME/CE and Curriculum Advisory Boards

PER is dedicated to promoting excellence in the delivery of patient care by providing quality educational opportunities. With an emphasis on oncology, our goal is to maintain and improve the competence and performance of multidisciplinary health care teams through effective continuing medical education (CME). We are assisted in this mission by CME/CE and Core Curriculum Advisory Boards. These boards provide input on educational needs and activities aimed at providing a multidisciplinary cancer care team with up-to-date information on evidence-based practice and emerging diagnostics and therapeutics in oncology.

CME/CE Advisory Board

This board focuses on the quality and effectiveness of PER's overall program as well as compliance with CME accreditation and regulatory issues. It comprises a minimum of 6 members, including, but not limited to, course directors, faculty/authors, community oncologists, oncology nurses, oncology pharmacists, legal/ethical counsel, and patient advocates.

Responsibilities include:

Performing annual evaluations of the overall program

Advising on educational needs

Reviewing evaluation data and making recommendations on current and new activities

Assuring regulatory compliance with all applicable agencies and rules

Participating in the CME reaccreditation process

Core Curriculum Advisory Boards

These boards are formed based on disease type, eg, breast, thoracic, GU/GYN, hematologic malignancies. Their purpose is to advise PER on the content and format of the educational activities, strategies for continual improvement, and innovation in teaching techniques. The boards primarily include active PER course directors and faculty who are experts in clinical care and/or research in oncology subspecialties.

Responsibilities for each assigned disease type include:

Advising on unmet educational needs

Reviewing evaluation data and recommending revisions to current activities

Proposing new activities and innovative formats

Recommending faculty and faculty development strategies

Assisting with learning outcome measures

Online CME Updates

THERAPY ADVANCES

Advances in Antiangiogenic Therapy for Metastatic Breast Cancer

Get updates on advances in antiangiogenic therapy for metastatic breast cancer. This program also includes a Q&A with our expert with selected questions from participants. Take part in this OncoLogue today.

Go to OncoLogue >>

NSCLC UPDATE

Treatment of a Male Former Smoker With Stage IV NSCLC and Squamous Histology

A personalized approach to the treatment of patients with NSCLC has recently gained increased recognition. Learn about optimal first- and second-line therapies based on tumor characteristics in advanced NSCLC.

Go to Case Study >>

TREATMENT DEVELOPMENTS

Treatment of Three Patients With Advanced Non–Small-Cell Lung Cancer

Several recent developments have improved treatment outcomes in patients with advanced NSCLC. Find out more.

Access here >>